TIDMNFX

RNS Number : 2884G

Nuformix PLC

23 July 2021

Nuformix plc

("Nuformix" or the "Company")

Posting of Annual Report and Notice of AGM

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, announces that its Annual Report and Accounts for the year ended 31 March 2021 and Notice of Annual General Meeting ("AGM") will be posted to shareholders later today and will be available in full to download from the Company's website (www.nuformix.com) shortly.

In accordance with the Listing Rule 9.6.1, a copy of these documents has been uploaded to National Storage Mechanism and will shortly be available for inspection at

https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The AGM will be held at Orega, 70 Gracechurch Street, London, EC3V 0HR on Tuesday, 24 August 2021 at 10.00am.

Shareholders should read the Notice of AGM for further details of arrangements for attendance at the AGM and voting.

Enquiries:

 
 Nuformix plc                                       +44 (0)1223 627222 
 Dr Anne Brindley, CEO 
 
 Allenby Capital Limited                           +44 (0)203 328 5656 
 Nick Athanas / George Payne (Corporate 
  Finance) 
 Stefano Aquilino / Matt Butlin (Sales 
  and Corporate Broking) 
 
 Walbrook PR 
 Anna Dunphy / Paul McManus / Kiki                 +44 (0)207 933 8780 
  Zaccagnini                                   nuformix@walbrookpr.com

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase 1-ready assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAFIFIADAIVFIL

(END) Dow Jones Newswires

July 23, 2021 08:35 ET (12:35 GMT)

Nuformix (LSE:NFX)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Nuformix Charts.
Nuformix (LSE:NFX)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Nuformix Charts.